Real-world use of and spending on new oral targeted cancer drugs in the US, 2011-2018

JAMAFu M, Naci H, Booth CM, et al. | December 08, 2021

Advertisement

Over the past decade, a substantial increase in the estimated use of new cancer drugs without documented clinical benefit has been noted, with major cost implications.

  • This cross-sectional study was conducted to evaluate the use of and spending on new oral targeted cancer drugs in US residents with employer-sponsored insurance between 2011 and 2018, stratified by the strength of available evidence of benefit.

  • Participants were 37,348 patients who received 1 or more of 44 new oral targeted cancer drugs.

  • An increase from 13% in 2011 to 59% in 2018 was evident in the proportion of patients receiving drugs without documented overall survival benefit; accounting for 52% of the $3.5 billion estimated cumulative spending on the new oral targeted cancer drugs by the end of 2018.

  • Overall, cancer drugs without documented overall survival advantages are adopted in the health system and account for substantial spending.

Read the full article on JAMA

Advertisement